An FDA report describing clinical data for Epidiolex® in the treatment of LGS or Dravet syndrome highlighted alanine aminotransferase (ALT) levels were three times the normal limit in 13% of Epidiolex® treated patients. This evidence concerns the gene GPT and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.